Publications
296
Citations
5,179
Est. group size
~65
Recurring co-author estimate
Active years
43
Publishing since 1984
Kerry A. Rogers studies chronic lymphocytic leukemia (CLL) and related blood cancers, focusing on comparing treatments such as ibrutinib, acalabrutinib, venetoclax, and CAR T-cell therapies. Much of this work uses real-world patient data and claims databases to evaluate treatment outcomes, dosing strategies, and healthcare costs outside of controlled clinical trials. The research aims to help clinicians choose among an expanding set of drug options for CLL and related conditions like hairy cell leukemia.
Publication output has grown substantially over the past decade, rising from about 10 papers in 2017 to a peak of 71 in 2023, with continued high output (20-30+ papers/year) through 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases
Journal of Comparative Effectiveness Research · 2025
- Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia
Blood · 2025
- Expert consensus opinion on the management of hairy cell leukemia in elderly patients
Leukemia & lymphoma/Leukemia and lymphoma · 2025
- Non-V600E <i>BRAF</i> mutations and treatment for hairy cell leukemia
Blood · 2024
- Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation
Blood Neoplasia · 2024
- The evolving frontline management of CLL: are triplets better than doublets? How will we find out?
Hematology · 2024
- GAIA/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia
The Lancet Oncology · 2024
- Choosing between CAR T-cell therapy and pirtobrutinib in double-refractory CLL.
PubMed · 2024
- Pairing obinutuzumab with venetoclax in relapsed CLL
Leukemia & lymphoma/Leukemia and lymphoma · 2024
- P645: IBRUTINIB FOR TREATMENT OF RELAPSED-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: A MATCHING-ADJUSTED INDIRECT COMPARISON OF 3 RANDOMIZED PHASE 3 TRIALS
HemaSphere · 2023
- Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma
Current Medical Research and Opinion · 2023
- A CAPTIVATEing Analysis for Higher-Risk CLL
Clinical Cancer Research · 2023
- 141 Novel emergence of cutaneous lupus erythematosus as adverse effect of Acalabrutinib Therapy for Chronic Lymphocytic Leukemia
Journal of Investigative Dermatology · 2023
- Real-world (RW) dosing patterns and outcomes among chronic lymphocytic leukemia (CLL) patients (pts) with or without an ibrutinib (IBR) dose adjustment (DA) in first-line (1L).
Journal of Clinical Oncology · 2023
- Comparative Effectiveness of Ibrutinib Flexible Dosing Treatment Strategies on Time to Next Treatment in a Largely Community-Based Claims Database: A Target Trial Emulation Study
Blood · 2023
- Blood×97
- Journal of Clinical Oncology×19
- Blood Advances×13
- Leukemia×11
- Clinical Lymphoma Myeloma & Leukemia×8
- Margaret S. Lucas
Medicine · The Ohio State University
- Jennifer A. Woyach
Medicine · The Ohio State University
- Jennifer A. Woyach
Medicine · The Ohio State University
- Seema A. Bhat
Medicine · The Ohio State University
- Jeffrey A. Jones
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile